Taipei, February 18th – OBIGEN Pharma announced the appointment of Ms. Patricia Chou as Chief Executive Officer. With extensive practical experience in international finance, capital market fundraising, and corporate growth strategy, Ms. Chou will lead the management team in advancing the company’s goal of entering the capital markets. This strategic move aims to expand operations and create greater value.
OBIGEN Pharma is the only company in Taiwan dedicated to the independent research and development of a new patented botulinum toxin. Its flagship product is currently in Phase II clinical trials in Taiwan. To accelerate technological innovation, internationalize product development, and secure capital market support, the company is planning an initial public offering. Previously, Mr. Frank Chen held both the Chairman and CEO roles. However, in compliance with managerial requirements post-IPO and to enhance professional specialization for sustained growth, the company has appointed Ms. Chou to take the helm.
Ms. Patricia Chou brings a wealth of financial and strategic expertise, having served as Chief Financial Officer (CFO) and Vice President of Strategic Planning at ScinoPharm Taiwan, CFO at Foresee Pharmaceuticals, and Vice President and CFO at Diamond Biofund. She was also recognized by Institutional Investor Magazine as one of the “Top Three Best CFOs in Asia’s Healthcare Industry” in 2014. Holding CPA qualifications in Taiwan, the U.S., and China, Ms. Chou has extensive experience spanning the biotechnology and semiconductor industries. With over 30 years of expertise in cross-border M&A and business development across Taiwan, the U.S., and China, her outstanding leadership is expected to bring new momentum and remarkable growth to OBIGEN Pharma.